Navigation Links
K2 Sports Announces New Endurance Suncare Product Rollout for 2008
Date:12/19/2007

leman and Mr. Coffee.

K2 Sports is what happens when fun meets science and technology. The company is driven by innovation and a passion for the sports enthusiast looking for unique and authentic lifestyle experiences. For more information on K2 Sports, its brands and products, visit http://www.K2sports.com.

About Outside Labs, Inc.

Outside Labs creates skin protection products for athletes who perform in demanding outdoor conditions. The founders, Nicolas Martens and John Bowen, meld world-class scientific expertise with a lifetime of action sports experience. Both have surfed and snowboarded extensively around the globe. Nic Martens earned a Ph.D. in biochemistry from the University of Cambridge in the UK and spent 13 years developing breakthrough healthcare products for Johnson & Johnson. John Bowen earned graduate degrees at both Caltech and Harvard, and was a scientist at NASA before partnering with Nic to launch Outside Labs. Their mission is to create skin products that give extraordinary protection for people in pursuit of their passion.


'/>"/>
SOURCE Outside Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. More Kids Are Suffering Sports Injuries
2. Blue Cross of California and the California Governors Council on Physical Fitness and Sports Launch Live Like a Champion Tour
3. NFL, NHL and NHLPA Team Up in Sports Concussion Education Campaign
4. Chicagos Premier Sports and Fitness Auction is Back!
5. Springer to publish Sports Engineering
6. American Physical Therapy Association Named Science Partner to the Presidents Council on Physical Fitness and Sports
7. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
8. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
9. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
10. HEI, Inc. Announces Sale of RFID Division Assets
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8PROSTVAC 28TM 29 Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late Stage Prostate Can 12379 1PROSTVAC 28TM 29 Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late Stage Prostate Can 12379 2PROSTVAC 28TM 29 Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late Stage Prostate Can 12379 3Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 1Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 2Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 3Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 4Back to normal 3A Surgery improves outcomes for spine patients 47438 1Back to normal 3A Surgery improves outcomes for spine patients 47438 2